Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Source filing unavailable
Q3 2013 · —
Revenue$1.74B$1.74B+0.3% vs Q3 2012 Net Income-$5.00M-$5.00MN/M vs Q3 2012 EPS Diluted$0.00$0.00N/M vs Q3 2012 Gross Profit$1,225,000,000+4.1% Operating Income$103,000,000N/M Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
$251,000,000
−7.7%
Free Cash Flowderived$194,000,000−14.2% Margins · derivedGross margin70.4%+2.6 pt vs Q3 2012
Operating margin5.9%+40.2 pt vs Q3 2012
Net margin-0.3%+38.0 pt vs Q3 2012